Iconovo AB (publ) (ICO.ST)
Iconovo AB (publ) operates in the Medical - Devices industry of the Healthcare sector, headquartered in Lund, SN, SE. The stock last traded at $1.21, down 0.82% on the session, giving a market capitalisation of $62.9M. Its beta of 0.42 implies it has historically moved less than the broad market.
Based in Lund, Sweden, Iconovo AB (publ) focuses on the creation and licensing of advanced inhalation delivery systems. Their product portfolio encompasses a variety of dry powder inhalers, such as the versatile multi-dose ICOres, the capsule-driven ICOcap, the single-use disposable ICOone, and the pre-metered ICOpre. Beyond these standard devices, the company also designs custom inhalation solutions, primarily catering to generic pharmaceutical firms. Iconovo is involved in significant collaborative ventures, including a project with Immune System Regulation AB to develop an inhaled COVID-19 vaccine using their ICOone inhaler, and a partnership with Respiratorius AB (publ) to formulate an inhalation treatment for COPD. The company was established in 2013.
Iconovo AB (publ) is most often compared with the following Healthcare names: